key: cord-0874004-cefotp6i
authors: Sarfraz, Zouina; Sarfraz, Azza; Barrios, Alanna; Garimella, Radhika; Dominari, Asimina; KC, Manish; Pandav, Krunal; Pantoja, Juan C.; Retnakumar, Varadha; Cherrez-Ojeda, Ivan
title: Cardio-Pulmonary Sequelae in Recovered COVID-19 Patients: Considerations for Primary Care
date: 2021-06-06
journal: J Prim Care Community Health
DOI: 10.1177/21501327211023726
sha: c4d6dd5217a35df1af7a9dded7ec0cb5b4fef740
doc_id: 874004
cord_uid: cefotp6i

BACKGROUND: Current literature lacks characterization of the post-recovery sequelae among COVID-19 patients. This review characterizes the course of clinical, laboratory, radiological findings during the primary infection period, and the complications post-recovery. Primary care findings are presented for long-COVID care. METHODS: Adhering to PRISMA guidelines, 4 databases were searched (PubMed, Embase, CINAHL Plus, Scopus) through December 5, 2020, using the keywords “COVID-19 and/or recovered and/or cardiovascular and/or long-term and/or sequelae and/or sub-acute and/or complication.” We included published peer-reviewed case reports, case series, and cross-sectional studies providing the clinical course of COVID-19 infection, and cardiopulmonary complications of patients who recovered from COVID-19, while making healthcare considerations for primary care workers. RESULTS: We identified 29 studies across 9 countries including 37.9% Chinese and 24.1% U.S. studies, comprising 655 patients (Mean Age = 45) with various ethnical backgrounds including Asian and European. Based on the WHO COVID-19 severity classification scale, initial disease severity was mild for 377 patients and severe for 52 patients. Treatments during primary infection included corticosteroids, oxygen support, and antivirals. The mean value (in days) for complication onset after acute recovery was 28 days. Complete blood counts and RT-PCR tests were the most common laboratory results described. In 22 of the studies, patients showed signs of clinical improvement and were prescribed medications such as anticoagulants or corticosteroids. CONCLUSION: Post-recovery infectious complications are common in long-COVID-19 patients ranging from mild infections to life-threatening conditions. International thoracic and cardiovascular societies need to develop guidelines for patients recovering from COVID-19 pneumonia, while focused patient care by the primary care physician is crucial to curb preventable adverse events. Recommendations for real-time and lab-quality diagnostic tests are warranted to establish point-of-care testing, detect early complications, and provide timely treatment.

Toward the end of December 2019, the COVID-19 outbreak resulted in massive fear worldwide. Although this outbreak initially occurred in Wuhan, a city in Hubei province, China, it rapidly spread throughout the world. The World Health Organization (WHO) announced that the COVID-19 pandemic as a health emergency of public concern on January 30, 2020. 1 The pandemic has drastically impacted all industries and sectors worldwide, placing an immense burden on the health care system. 2 COVID-19 has a wide array of clinical presentations ranging from nonspecific symptoms such as fever, fatigue, and diarrhea to severe respiratory and cardiovascular complications, including acute respiratory distress syndrome (ARDS) and multiple organ failure leading to mortality. 3 As a result of the data gathered from numerous clinical trials conducted worldwide, there has been ongoing concern regarding the persistence of the SARS-CoV-2 virus in the post-acute period. 4 Due to the limited understanding of the clinical 

All studies included in this review were published through December 5, 2020 . Twenty studies were case reports, 5 were retrospective cohorts, 2 were prospective observational studies, 1 was a case-control, and 1 was a case series (Table 1) . Nine countries were represented with the largest data derived from studies in China (37.9%) and the United States (24.1%). The total number of included participants was 655, with a mean age of 45, comprising of various ethnical backgrounds including Asian and European. A total of 419 patients with mild symptoms and 59 patients with severe symptoms were included. Patient outcomes were notably well due to recovery from infection in 22 of the studies where they recovered or were prescribed medications for underlying thromboembolic conditions including anticoagulants. a male predominance. About 12 studies reported complete clinical remission, 4 of them reported intensive care unit admission (ICU), 9 mentioned hospital admission, and an average of 34 days from the primary infection to the presence of complication was reported across 11 studies. The major complication during hospital stay was a respiratory failure even though it was only reported in only 2 studies. Treatment was provided in detail in 12 studies, encompassing oxygen support, antivirals, antibiotics, corticosteroids, and anticoagulants. Most patients described shortness of breath, upper respiratory tract like symptoms, and dyspnea as main presenting features. RT-PCR tests and Computed Tomography (CT) Scans were the most commonly recommended tests (Table 3) . 

The complications and clinical course of all included COVID-19 patients with specific characteristics such as endocrine, hematological, ophthalmological, and neurological details are described in Supplemental Table 1 . Of all the aforementioned patients, 70% of them were hospitalized, and 30% of them were admitted to the intensive care unit (ICU). The patients were treated mainly with oxygen supportive therapy, steroids, antibacterial, and antivirals. All patients were confirmed to have COVID-19 with a positive PCR test, initial complete blood work was followed, in addition to inflammatory markers and special panels according to each underlying comorbidity. Lung CT scans were followed in 60% of cases; 70% of the patients develop resolution of the acute clinical syndrome, even though a longer follow up study is suggested to observe the full resolution of symptoms or complete basal return. In 4 (28.6%) of the pulmonary studies, pulmonary embolism (PE) was present. In 2 (14.3%) of studies, pneumothorax was noted, and recurrence of infection was observed in 5 (35.7%) of the studies. Of the cardiovascular studies, 4 (80%) required an additional test to detect abnormal functionality (Tables 3  and 4 ). Relevant important points for primary care were extracted and described for cardiovascular and pulmonary cases (Tables 3 and 4 ). Despite the heterogeneity of the included articles, the need for guidelines, and the demand for follow up studies to describe duration or clinical course evolution is significant.

This systematic review analyzes the cardio-pulmonary sequelae in recovered COVID-19 patients while making considerations for primary care. With the data gathered from numerous COVID-19 clinical studies conducted across the world, researchers have been able to demonstrate that despite apparent complete recovery from COVID-19, patients may suffer from post-recovery sequelae. However, there has been no consensus on the defining characteristics of post-acute COVID-19 syndrome. Commonly reported symptoms in the post-acute COVID-19 phase are fatigue, dyspnea, joint pain, and chest pain. 36 Cardiopulmonary consequences have been reported in the recovery phases, and have considerable implications for long-term health consequences. 29 

Wu et al 39 report ARDS in 40% of patients infected with SARS-CoV-2 infection, with over 20% in the older age groups. Burnham et al 40 find that persistent inflammation of alveolar epithelium and hypercytokinemia in SARS-CoV-2 infection leads to fibroproliferative changes which include fibroblast accumulation and deposition of extracellular matrix collagen in the lung parenchyma. The resulting disruption of the balance between profibrotic and antifibrotic factors leads to pulmonary fibrosis which is observed in a subset of patients as protracted sequelae to ARDS. 40 Pulmonary fibrosis is characterized by the presence of an unusual interstitial pneumonia-like fibrotic abnormality on high-resolution computed tomography (HRCT) and this is linked to a more increased incidence of rapid progression of the disease. [41] [42] [43] [44] A prospective study was conducted by Liu et al including 149 patients who were discharged from various hospitals in Wuhan, China following recovery from COVID-19 pneumonia. Patients were followed up during the first, second, and third-weeks post-discharge. The results showed that patients younger than 44 years had a significantly higher percentage of complete radiological resolution than patients who were older than 44 years. Out of the various lesions observed, the most predominant were ground-glass opacity in 83.9% of patients followed by a fibrous stripe in 54.4% and only 22.1% showed thickening of the adjacent pleura. The number of patients testing positive for each lesion decreased gradually over 3 weeks and the radiological resolution was more evident in patients with ground-glass opacity and fibrous stripe in the first and third weeks, respectively. Most residual lung abnormalities were absorbed throughout recovery, suggesting the importance of radiological assessment 2 weeks post-discharge. 30 The importance of determining the timing and standpoints of radiological resolution in COVID-19 patients can provide further insight into deciding which patient groups need long term monitoring.

Mo et al 31 observed that COVID-19 survivors who had been discharged from the hospital demonstrated pulmonary function abnormalities, the most common among those being diffusion capacity impairment, followed by restrictive ventilatory defects. Zhao et al 32 Patients without ARDS were less likely to be associated with post-COVID radiological and functional changes. 47 There is a lack of detailed knowledge on the pathophysiology of the disease, taking into consideration the available studies, following up on discharged COVID-19 patients, assessing them using radiological and pulmonary tests, and managing potential issues are all necessary precautionary measures.

Myocardial injury is defined by laboratory testing, namely by an increased troponin level, which has been documented as a severe COVID-19 sequela. 48 A median of 71 days post COVID-19 diagnosis, cardiac involvement was reported by Puntmann et al 29 in 78% patients, and 60% revealed myocardial inflammation on cardiac magnetic resonance imaging in a Germany study. Long et al 49 reported common cardiovascular sequelae in COVID-19 as myocarditis, thromboembolic disease, and arrhythmias. The alterations in normal cardiovascular physiology, coagulation state, and basal metabolism observed, including those with RNA-sequencing analysis, reveal increased levels of angiotensin-converting enzyme-2 (ACE-2) in cardio-myocytes thereby increasing the possibility of direct myocardial tissue infection in high-risk patients. 47, 48 As per Siripanthong et al, 50 the ACE-2 receptor on the myocardium may be used by SARS-CoV-2 to gain entry into cells, triggering the release of massive amounts of pro-inflammatory cytokines, immune hyper-activation, and myocardial tissue damage. Cardiac tropism, an impaired cardio-protective function of ACE2 downregulated by SARS-CoV-2, and elevated proinflammatory cytokine release are potential pathological mechanisms. [51] [52] [53] Sardari et al 13 write that myocarditis may occur due to the residual myocardial inflammation in COVID-19. Evidence of SARS-CoV-2 mRNA in the myocardium has been observed by Tavazzi et al 54 and Wenzel et al 55 on autopsy and endomyocardial biopsies, suggestive of myocarditis. Underlying cardiovascular disease (CVD) may predispose patients to SARS-CoV-2 myocarditis. 55 Further, cardiovascular complications caused due to COVID-19 or prevalent before infection must be addressed. A meta-analysis finds that the pooled incidence of acute cardiovascular complications during the COVID-19 pandemic is 1.4%. However individuals with COVID-19 who presented with concomitant stroke were more likely to have pre-existing cardiovascular comorbidities not limited to arrhythmias, myocarditis, and thromboembolism, linked to severe COVID-19 infection. The patterns of large vessel occlusions and multi-territory infracts suggests that thromboembolism and/or cerebral thrombosis may potentially be causative pathways for COVID-19 disease. 56 The mortality and morbidity due to cardiovascular complications in COVID-19 patients are higher when there is evidence of myocardial involvement, as implicated by Mitrani et al 57 In the setting of myocarditis, myocyte lysis releases proteins with abnormal epitopes and with a similar structure to those present in the virus. Błyszczuk 58 and Gangaplara et al 59 state that these can be recognized by major histocompatibility complex and seemingly add autoimmune components to cardiac injury. Chapman et al 60 presume that these mechanisms of tissue damage cause long-term complications in COVID-19 patients. Varga et al 61 form an association between endothelitis and multi-organ failure with evidencing direct viral infection of the endothelium. Additionally, possible cytopathic effects and increased myocardial cell death after inducible SARS-CoV-2 on induced pluripotent stem cells (iPSC) have also been identified by Bose and McCarthy. 62 Multiple studies have shown an increased rate of arrhythmias in patients recovering from viral myocarditis. A study by Blagova et al 63 revealed that among 19 cases of "idiopathic" arrhythmias, 78.9% were identified as immunemediated inflammatory after the endomyocardial biopsy was performed, finding cardiotropic viruses as etiologic agents. Since the beginning of the COVID-19 pandemic, thrombotic complications have been reported in critically ill patients. The term MicroCLOTS (microvascular COVID-19 Lung Vessels Obstructive Thromboinflammatory syndrome) due to microvascular pulmonary thrombosis is currently being used in literature to describe manifestations of the disease. The high incidence of micro thrombosis in the lungs was noted in 80% autopsies of COVID-19 cases by Dolhnikoff et al 64 Klok et al 65 report the incidence of venous thromboembolism as 31%, leading to pulmonary embolism (80%) and arterial thrombosis (3.7%). Further studies are needed to specifically describe cardiovascular complications post COVID-19, especially screening for the incidence of heart failure. Close monitoring of patients is pertinent, even in cases with no signs of cardiovascular impairment.

Although the impact of long-term COVID-19 sequelae is still unclear, a large number of patients will likely experience persistent symptoms, especially in those geographical regions where large outbreaks occurred. Various strategies are being evaluated not only to treat COVID-19 patients but also to prevent as many detrimental complications as possible. Greenhalgh et al describe post-acute COVID-19 as "Long COVID," which is a multisystem disease. 66 Notably, cardio-pulmonary complications may occur after mild infections as well, requiring attention by primary care providers. 66 For a general practitioner, it is essential to note improvements over 3 weeks and subsequent weeks/months. The symptoms may manifest in any bodily organ, however, the most common ones include cough (dry versus productive), fever, fatigue during long COVID. Uncommon symptomatology worth considering by the primary care practitioner includes mood swings, palpitations, anxiety, hypotension, and/or skin rashes (ie, maculopapular). The nonspecific (ie, lung burn, brain fog) versus the specific complications (ie, stroke, pulmonary embolism, myocarditis, heart failure) must be distinguished clinically upon a visit to a primary care practitioner and specific presentations recommended to specialist centers. A clinical insight for long COVID is the fact that the presentation during acute COVID does not directly relate to the severity of findings 6 months later (ie, if a patient had severe pneumonia on the acute onset, the sequelae may be less severe as compared to those who had less severe acute complications). Based on the limited evidence in published literature so far, patients with long COVID may have no access to specialist care. To improve patient outcomes, it is essential to adopt a community-based, interprofessional rehabilitation pattern of care by promoting remote technologies, telehealth appointments with a primary care physician, and adopting otherwise locally relevant solutions.

The implementation of a multi-disciplinary approach to identify, and prevent the impact of long-term health outcomes of COVID-19 across different organs, including cardiopulmonary, as well as the well-being of recovered patient groups is necessary to elucidate the potential classification of complications in post-acute COVID-19. 67 An example of how rehabilitation can successfully be applied to post-COVID-19 patient management is offered by Shan et al, 68 who describes the case of a woman at about 80 years of age gradually returning to her premorbid independent condition after severe COVID-19 complicated by acute respiratory distress syndrome (ARDS) following 10 days of post-acute inpatient pulmonary rehabilitation. Interestingly, current knowledge on the long-term impact of the SARS-CoV-2 infection to an important degree comes from previous epidemics, caused by severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). However, deficits associated with the current pandemic are expected to be more critical, given the magnitude of the pandemic.

A practical approach is to follow up on all hospitalized patients with chest radiography and oxygen saturation measurements, as recommended by the British Thoracic Society. 69 However, the American Thoracic Society/ European Respiratory Society does not make any suggestion in favor of or against routine pulmonary function tests (PFTs), chest CT scans, transthoracic echocardiography (TTE), and cardiopulmonary exercise testing (CPET) within 30 to 60 days. 70 Preliminary evidence suggests the development of respiratory sequelae as early as 2 weeks after discharge, especially among patients with elevated inflammatory markers and D-dimer levels. 31, 32 Data suggests the frequent occurrence of pulmonary fibrosis, arrhythmias, and cardiomyopathies among survivors over 2 months after recovery. 29 All patients requiring further investigation may be referred to as pulmonologists and cardiologists for further evaluation of pulmonary (PFTs and chest CT scans) and cardiac (TTE and CPET) assessment within 2 to 3 months of recovery. It is also necessary to establish a baseline time to follow recovery. Admittedly, resource-limited settings may not be able to conduct such tests. Consequently, evidence suggests routine testing of pulmonary and cardiac sequelae in COVID-19 is beneficial within 30 to 90 days of discharge in all previously hospitalized patients.

In the United States, 3 different phases of the pandemic have been documented. At the onset, in April, 2020 there was limited testing. During the second phase in July, 2020, social distancing among other factors contributed to infectivity. However, testing was widely available to most of the public. The third phase at the onset of 2021 was potentially connected with seasonal respiratory viruses. These are uncontrollable limitations in post-infection pulmonary-cardiovascular tests that are presented with external factors contributing to varied test outcomes. The other limitation of our study relates to its retrospective nature. Many of the included studies were case reports and, therefore, findings may not be generalizable and the causality within those may not be fully proven. As the majority of the studies were from China, some of the presentations could be influenced by the ethnicity-related characteristics of the region.

With limited insight on the sequelae of COVID-19 infection, a holistic approach is required that incorporates primary care. Complications are frequently observed in patients recovering from COVID-19, ranging from mild to life-threatening conditions. Patients who presented with ARDS, PE, arrhythmia, myocarditis, or other cardiopulmonary complications during the acute phase necessitate multi-speciality care and follow-up for long-COVID. It is currently unclear whether ARDS or other complications due to COVID-19 or other causative factors will have different long-term outcomes. Follow-up of clinically recovered patients with cardiopulmonary imaging studies could be crucial for the evaluation of adverse events caused by SARS-CoV-2 infection. Primary health care forms a critical foundation for gatekeeping timely and effective support during the COVID-19 pandemic. Through primary care services, it is possible to provide rehabilitation and support to recovering patients in light of a greater volume of patients requiring rehabilitation in the post-acute COVID-19 infectious phase. Physicians across all healthcare levels should be alert on and monitor patients for possible adverse events after recovery from SARS-CoV-2 infection. International societies ought to develop guidelines for patients recovering from COVID-19 and recommend the routine monitoring of these patients to establish cardiopulmonary testing, detect early complications, and provide timely treatment. Importantly, observational studies and clinical trials reporting data on acute and post-acute infectious phases will help elucidate the health outcomes, attributable to COVID-19 and underlying medical conditions. 

World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)

The socio-economic implications of the coronavirus pandemic (COVID-19): a review

COVID-19 and multiorgan response

COVID-19 reinfection: myth or truth? SN Compr Clin Med

Clinical management of COVID-19 interim guidance

Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 7)

Incomplete and late recovery of sudden olfactory dysfunction in COVID-19

Subacute thyroiditis after sars-COV-2 infection

Long-term effects of COVID-19 in a patient on maintenance dialysis

A case of COVID-19 infection with delayed thromboembolic complication on warfarin

Spontaneous pneumothorax following COVID-19 pneumonia

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review

Myocarditis detected after COVID-19 recovery

Cranial nerves impairment in post-acute oropharyngeal dysphagia after COVID-19: a case report

A case-report of widespread pulmonary embolism in a middle-aged male seven weeks after asymptomatic suspected COVID 19 infection

Positive SARS-CoV-2 RNA recurs repeatedly in a case recovered from COVID-19: dynamic results from 108 days of follow-up

A case of a readmitted patient who recovered from COVID-19 in Chengdu

Saddle pulmonary embolism and thrombus-in-transit straddling the patent foramen ovale 28 days after COVID symptom onset

Successful aspiration thrombectomy in a patient with submassive, intermediaterisk pulmonary embolism following COVID-19 pneumonia

Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report

Sudden severe thrombocytopenia in a patient in the recovery stage of COVID-19

Prolonged dermatological manifestation 4 weeks following recovery of COVID-19 in a child

Increased physiological dead space in mechanically ventilated COVID-19 patients recovering from severe acute respiratory distress syndrome: a case report

A case presentation for positive SARS-CoV-2 RNA recurrence in a patient with a history of type 2 diabetes that had recovered from severe COVID-19

A case of spontaneous pneumothorax 21 days after diagnosis of coronavirus disease 2019 (COVID-19) pneumonia

Papillophlebitis in a COVID-19 patient: inflammation and hypercoagulable state

Tracheal stenosis after tracheostomy for mechanical ventilation in COVID-19 pneumonia -a report of 2 cases from Northern Italy

Case report: recurrent clinical symptoms of COVID-19 in healthcare professionals: a series of cases from Brazil

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

The pulmonary sequalae in discharged patients with COVID-19: A short-term observational study

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Myocardial Pathology Evaluated Through scrEening Cardiac Magnetic Resonance (COMPETE CMR)

Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection

Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging

Persistent symptoms in patients after acute COVID-19

Long term respiratory complications of covid-19

Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network -United States

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance

Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants

Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease

Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory

Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases

The natural history of progressive fibrosing interstitial lung diseases

Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect

Six-month follow-up chest CT findings after severe COVID-19 pneumonia

Long-term health consequences of COVID-19

Cardiovascular complications in COVID-19

Recognizing COVID-19-related myocarditis: the possible pathophysiology and proposed guideline for diagnosis and management

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

The science underlying COVID-19: implications for the cardiovascular system

COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab

Stroke in COVID-19: a systematic review and meta-analysis

COVID-19 cardiac injury: implications for long-term surveillance and outcomes in survivors

Myocarditis in humans and in experimental animal models

Coxsackievirus B3 infection leads to the generation of cardiac myosin heavy chain-α-reactive CD4 T cells in A/J mice

Long-term outcomes in patients with type 2 myocardial infarction and myocardial injury

Endothelial cell infection and endotheliitis in COVID-19

Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19

Myocardial biopsy in "idiopathic" atrial fibrillation and other arrhythmias: nosological diagnosis, clinical and morphological parallels, and treatment

Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

Management of post-acute covid-19 in primary care

The war on COVID-19 pandemic: role of rehabilitation professionals and hospitals

Postacute inpatient rehabilitation for COVID-19

British Thoracic Society guidance on respiratory follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia

Updated guidance on the management of COVID-19: from an

The only exception to the severity scale employed is the paper by Wei 6 which relied on the "Diagnosis and Treatment Protocol of Novel Coronavirus issued by the National Health Commission of the People's Republic of China." Data were tabulated into a shared spreadsheet customized for this review. All tables were optimized before commencing data entry using 6 sample articles included in the review to ensure optimal presentation of findings. Articles selected for the final analysis were independently graded by 2 authors (AS and ZS) for quality using the Newcastle-Ottawa Scale (NOS).No funding was obtained for this study.

The search yielded 1091 studies. After removing 431 duplicates, 660 articles were reviewed for title and abstract. After the initial screening, only 167 articles met the inclusion criteria and underwent full-text evaluation. Records that consisted of commentaries, editorials, or reviews that did not meet our criteria were removed, generating a final list of 29 articles (Figure 1 ).

All authors acknowledge Jack Michel MD (Founder, Larkin Health System, South Miami, FL, USA) for his active support during the course of drafting this paper. All authors are indebted to Larkin Community Hospital, South Miami, FL, USA for being a driving force in promoting COVID-19 scholarly activities.

The authors contributed equally to all aspects of the article. AS and ZS are co-guarantors of the paper.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

The author(s) received no financial support for the research, authorship, and/or publication of this article. 

Supplemental material for this article is available online.